Investigation of Vancomycin Resistance in Staphylococcus aureus Strains Detected by Microdilution and Agar Screening Method

Vancomycin Resistance in Staphylococcus aureus Strains

vancomycin resistance in staphylococcus aureus strains

0

Novel screening agar for detection of vancomycin-nonsusceptible Staphylococcus aureus.

In January 2006, the Clinical and Laboratory Standards Institute (CLSI) updated breakpoints for vancomycin susceptibility testing for Staphylococcus aureus such that an MIC greater than 2 mg/liter was considered to represent nonsusceptibility to vancomycin. Previously, an MIC of 4 mg/liter had been considered to represent susceptibility. Additionally, in 2009, the CLSI altered the guidelines fo...

Prevalence of Vancomycin Resistance in Methicillin-Resistant Staphylococcus Aureus

Background & Aims: Staphylococcus aureus is one of the most common pathogens in nosocomial infections. Vancomycin is the most important therapeutic drug of choice for treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) strains. Therefore, vancomycin-resistant Staphylococcus aureus (VRSA) or vancomycin-intermediate Staphylococcus aureus (VISA) strains are warning...

Vancomycin Resistance in Staphylococcus aureus


The evolution of Staphylococcus aureus during the modern antibiotic era has been delineated by distinct strain emergence events, many of which include acquisition of antibiotic resistance. The relative high burden of methicillin-resistant S. aureus (MRSA) in healthcare and community settings is a major concern worldwide. Vancomycin, a glycopeptide antibiotic that inhibits cell wall biosynthesis...